Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00441519 · ClinicalTrials.gov registry record · Phase 1
A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated Aspirin
A Phase 1 study, sponsored by POZEN.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT00441519: Completed Phase 1 study, sponsored by POZEN.
NCT00441519 is a Phase 1 study that has completed, run by POZEN. The registered enrollment target is 80 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00441519, a Phase 1 study, has completed, sponsored by POZEN.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
To compare the gastroprotective effects of a once-daily dose of PA 325 combination tablet
Interventions
- DRUG aspirin
- DRUG omeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2007-02 |
| Est. Completion | 2007-04 |
| Phase | Phase 1 |
What the finished NCT00441519 record still lists
NCT00441519 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher).
The record links to 0 conditions, and to 2 interventions - of which aspirin is the first listed.
NCT00441519 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00441519 about?
NCT00441519 is a clinical study titled "A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated Aspirin". To compare the gastroprotective effects of a once-daily dose of PA 325 combination tablet
What is the current status of trial NCT00441519?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2007-02. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00441519?
The interventions under investigation include: aspirin (DRUG), omeprazole (DRUG).
Who is sponsoring clinical trial NCT00441519?
This trial is sponsored by POZEN, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00441519's enrollment target sits among peer trials
80 672nd of 2000 higher than 1,305 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia